ANTIHYPERTENSIVE EFFICACY OF OLMESARTAN MEDOXOMIL, A NEW ANGIOTENSIN II RECEPTOR ANTAGONIST, AS ASSESSED BY AMBULATORY BLOOD PRESSURE MEASUREMENTS

Olmesartan medoxomil is a new angiotensin II receptor blocker. In this randomized, double-blind, placebo-controlled study, the efficacy and safety of olmesartan medoxomil was assessed in 334 patients with moderate to severe essential hypertension. Patients were randomized to receive placebo; 5, 20,...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	J. M. Neutel, W. J. Elliott, J. L. Izzo, C. L. Chen, H. N. Masonson
Format:	Artigo
Sprog:	Russo
Udgivet:	«FIRMA «SILICEA» LLC 2011-04-01
Serier:	Российский кардиологический журнал
Fag:	moderate to severe essential hypertension olmesartan medoxomil antihypertensive efficacy safety 24-hour ambulatory blood pressure monitoring
Online adgang:	https://russjcardiol.elpub.ru/jour/article/view/1155
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!